Norris Medicines Live BSE/NSE | Norris Medicines Fundamenta data | Norris Medicines Balance sheet | Norris Medicines Quarterly Results | Norris Medicines Profit & Loss

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

4.45
N/A
10

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

18.59
N/A
-1.68

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

10 Years
5 Years
3 Years

-
-2.72
-7.35

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-
-
54.19

PAT CAGR (%)

10 Years
5 Years
3 Years

-
10.07
29.70

P:E (Median)

8 Years
5 Years
3 Years

P:BV (Average)

8 Years
5 Years
3 Years

EV:EBITDA (Average)

8 Years
5 Years
3 Years

Quarterly Results

Standalone Figures in Rs. Crores

Description Jun 20 Jun 19 Var% Mar 20 Mar 19 Var% Dec 19 Dec 18 Var% Sep 19 Sep 18 Var%
Net Sales 2 3 -38% 1 4 -62% 2 4 -57% 2 4 -54%
Expenses 2 3 -41% 2 3 -16% 2 5 -54% 2 4 -42%
EBITDA 0 0 - -1 1 - 0 -1 - -1 0 -
EBIDTM 1% -5% -67% 25% -22% -15% -41% -11%
Other Income 0 0 200% 0 0 100% 0 0 0 0 0 0
Interest 0 0 -39% 0 0 89% 0 0 -11% 0 0 6%
Depreciation 0 0 0% 0 0 5% 0 0 0% 0 0 0%
PBT 0 0 - -1 1 - -1 -1 - -1 -1 -
Tax 0 0 0 -1 0 - 0 0 0 0 0 0
PAT 0 0 - -1 1 - -1 -1 - -1 -1 -
PATM -14% -16% -41% 25% -41% -23% -62% -21%
EPS -0.25 -0.48 - -0.55 0.88 - -0.72 -0.96 - -1.09 -0.79 -

Description Jun 20 Jun 19 Var% Mar 20 Mar 19 Var% Dec 19 Dec 18 Var% Sep 19 Sep 18 Var%
Net Sales 0 0 0 0 0 0 0 0 0 0 0 0
Expenses 0 0 0 0 0 0 0 0 0 0 0 0
EBITDA 0 0 0 0 0 0 0 0 0 0 0 0
EBIDTM 0% 0% 0% 0% 0% 0% 0% 0%
Other Income 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0
PBT 0 0 0 0 0 0 0 0 0 0 0 0
Tax 0 0 0 0 0 0 0 0 0 0 0 0
PAT 0 0 0 0 0 0 0 0 0 0 0 0
PATM 0% 0% 0% 0% 0% 0% 0% 0%
EPS 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0

Annual Results

Standalone Figures in Rs. Crores

Description TTM Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12
Net Sales 7 16 14 20 19 19 21 21 16 Net Sales Growth -54% 20% -34% 8% 1% -10% -3% 37% Cost Of Goods Sold 4 6 3 10 9 9 14 13 8 Gross Profit 3 10 10 10 10 10 7 8 7 GP Margin 43% 61% 75% 49% 51% 51% 34% 39% 47% Total Expenditure 9 17 15 21 18 17 22 20 14 Power & Fuel Cost - 2 2 2 2 2 1 1 1 % Of Sales - 9% 12% 8% 9% 9% 7% 6% 7% Employee Cost - 4 5 5 5 4 4 3 2 % Of Sales - 23% 36% 26% 26% 22% 18% 15% 15% Manufacturing Exp. - 4 4 2 1 1 2 1 0 % Of Sales - 27% 32% 9% 6% 4% 8% 4% 2% General & Admin Exp. - 1 1 1 1 1 1 1 1 % Of Sales - 4% 8% 6% 5% 4% 4% 5% 4% Selling & Distn. Exp. - 0 0 0 0 0 0 0 0 % Of Sales - 0% 1% 1% 1% 3% 2% 2% 1% Miscellaneous Exp. - 0 0 0 0 0 0 0 1 % Of Sales - 0% 0% 0% 0% 0% 0% 0% 7% EBITDA -2 -1 -2 0 1 2 -1 1 2 EBITDA Margin -30% -4% -14% 0% 4% 9% -5% 5% 11% Other Income 0 0 0 0 0 0 0 0 0 Interest 1 1 1 1 1 1 0 0 0 Depreciation 1 1 1 1 1 1 1 1 1 PBT -3 -2 -3 -1 0 0 -3 0 1 Tax -1 0 -1 0 0 1 -1 0 1 Tax Rate 24% 16% 21% 36% 129% 10,500% 43% 0% 87% PAT -3 -2 -3 -1 0 -1 -1 0 0 PAT before Minority Interest -3 -2 -3 -1 0 -1 -1 0 0 Minority Interest 0 0 0 0 0 0 0 0 0 PAT Margin -39% -10% -18% -4% 0% -6% -7% 0% 1% PAT Growth 0% 33% -226% -2,025% 104% 28% -1,511% -212% EPS -2.61 -1.68 -2.51 -0.77 0.04 -1.04 -1.45 -0.09 0.08

Description

TTM

Mar 19

Mar 18

Mar 17

Mar 16

Mar 15

Mar 14

Mar 13

Mar 12

Net Sales

Net Sales Growth

-54%

20%

-34%

-10%

-3%

37%

Cost Of Goods Sold

Gross Profit

GP Margin

43%

61%

75%

49%

51%

34%

39%

47%

Total Expenditure

Power & Fuel Cost

% Of Sales

12%

Employee Cost

% Of Sales

23%

36%

26%

22%

18%

15%

Manufacturing Exp.

% Of Sales

27%

32%

General & Admin Exp.

% Of Sales

Selling & Distn. Exp.

% Of Sales

Miscellaneous Exp.

% Of Sales

EBITDA

-2

-1

-2

-1

EBITDA Margin

-30%

-4%

-14%

-5%

11%

Other Income

Interest

Depreciation

PBT

-3

-2

-3

-1

-3

Tax

-1

Tax Rate

24%

16%

21%

36%

129%

10,500%

43%

87%

PAT

-3

-2

-3

-1

PAT before Minority Interest

-3

-2

-3

-1

Minority Interest

PAT Margin

-39%

-10%

-18%

-4%

-6%

-7%

PAT Growth

33%

-226%

-2,025%

104%

28%

-1,511%

-212%

EPS

-2.61

-1.68

-2.51

-0.77

0.04

-1.04

-1.45

-0.09

0.08

Results Balance Sheet

Standalone Figures in Rs. Crores

Description Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12
Shareholder's Funds 0 2 5 5 5 6 8 8 Share Capital 10 10 10 10 10 10 10 10 Total Reserves -10 -8 -5 -5 -5 -4 -2 -2 Non-Current Liabilities 8 5 6 6 6 5 6 1 Secured Loans 0 0 0 0 0 0 0 0 Unsecured Loans 11 8 7 7 7 7 7 2 Long Term Provisions 0 0 0 0 0 0 0 0 Current Liabilities 9 11 10 5 5 8 8 7 Trade Payables 4 5 4 3 3 6 6 3 Other Current Liabilities 1 2 2 2 1 1 1 1 Short Term Borrowings 3 4 4 0 1 0 0 3 Short Term Provisions 1 1 1 1 1 1 0 0 Total Liabilities 18 18 20 17 17 19 22 16 Net Block 9 9 10 8 9 9 8 8 Gross Block 28 27 28 26 25 24 22 21 Accumulated Depreciation 19 18 18 17 17 15 14 13 Non Current Assets 10 11 11 10 10 10 10 10 Capital Work in Progress 0 0 0 0 0 0 1 0 Non Current Investment 0 0 0 0 0 0 0 0 Long Term Loans & Adv. 1 1 1 1 1 1 1 1 Other Non Current Assets 0 0 0 0 0 0 0 0 Current Assets 7 8 9 7 7 9 12 6 Current Investments 0 0 0 0 0 0 0 0 Inventories 4 4 4 3 2 3 6 2 Sundry Debtors 3 2 5 3 4 5 5 3 Cash & Bank 0 0 0 0 0 0 1 1 Other Current Assets 1 0 0 0 1 0 0 0 Short Term Loans & Adv. 1 1 1 1 0 0 0 0 Net Current Assets -1 -3 -1 2 2 1 4 -1 Total Assets 18 18 20 17 17 19 22 16

Description

Mar 19

Mar 18

Mar 17

Mar 16

Mar 15

Mar 14

Mar 13

Mar 12

Shareholder's Funds

Share Capital

Total Reserves

-10

-8

-5

-4

-2

Non-Current Liabilities

Secured Loans

Unsecured Loans

Long Term Provisions

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Liabilities

Net Block

Gross Block

Accumulated Depreciation

Non Current Assets

Capital Work in Progress

Non Current Investment

Long Term Loans & Adv.

Other Non Current Assets

Current Assets

Current Investments

Inventories

Sundry Debtors

Cash & Bank

Other Current Assets

Short Term Loans & Adv.

Net Current Assets

-1

-3

-1

Total Assets

Cash Flow

Standalone Figures in Rs. Crores

Description Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12
Cash From Operating Activity -2 1 -1 1 1 1 -1 0 PBT -2 -3 -1 0 -1 -1 0 1 Adjustment 1 1 1 1 3 0 1 1 Changes in Working Capital -1 3 -1 0 -1 2 -2 1 Cash after chg. in Working capital -2 1 -1 1 1 1 -1 2 Interest Paid 0 0 0 0 0 0 0 0 Tax Paid 0 0 0 0 0 0 0 0 Other Direct Exp. Paid 0 0 0 0 0 0 0 0 Extra & Other Items 0 0 0 0 0 0 0 -2 Cash From Investing Activity 0 0 -2 0 -1 -2 -1 -1 Net Fixed Assets 0 0 -2 0 -1 -2 -1 Net Investments 0 0 0 0 0 0 0 Others 0 -1 0 0 0 0 0 Cash from Financing Activity 2 -1 3 -1 0 0 2 0 Net Cash Inflow / Outflow 0 0 0 0 0 0 0 -1 Opening Cash & Equivalents 0 0 0 0 0 1 1 1 Closing Cash & Equivalent 0 0 0 0 0 0 1 1

Description

Mar 19

Mar 18

Mar 17

Mar 16

Mar 15

Mar 14

Mar 13

Mar 12

Cash From Operating Activity

-2

-1

PBT

-2

-3

-1

Adjustment

Changes in Working Capital

-1

-2

Cash after chg. in Working capital

-2

-1

Interest Paid

Tax Paid

Other Direct Exp. Paid

Extra & Other Items

-2

Cash From Investing Activity

-2

-1

-2

-1

Net Fixed Assets

-2

-1

-2

-1

Net Investments

Others

-1

Cash from Financing Activity

-1

Net Cash Inflow / Outflow

-1

Opening Cash & Equivalents

Closing Cash & Equivalent

Financial Ratios

Standalone

Description Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12
Book Value (Rs.) 0 2 5 5 5 6 8 8 ROA -9% -13% -4% 0% -6% -7% 0% 0% ROE -138% -76% -16% 1% -18% -21% -1% 1% ROCE -9% -17% -4% 4% 4% -15% 0% 5% Fixed Asset Turnover 0.59 0.49 0.77 0.74 0.75 0.90 0.99 0.74 Receivable days 61 96 67 63 87 90 70 71 Inventory Days 92 109 63 57 51 73 69 58 Payable days 94 100 57 53 87 98 85 85 Cash Conversion Cycle 59 106 73 67 51 65 53 43 Total Debt/Equity 38.16 5.52 2.47 1.41 1.54 1.19 0.90 0.66 Interest Cover -2 -4 -1 1 1 -5 -2 10

Description

Mar 19

Mar 18

Mar 17

Mar 16

Mar 15

Mar 14

Mar 13

Mar 12

Book Value (Rs.)

ROA

-9%

-13%

-4%

-6%

-7%

ROE

-138%

-76%

-16%

-18%

-21%

-1%

ROCE

-9%

-17%

-4%

-15%

Fixed Asset Turnover

0.59

0.49

0.77

0.74

0.75

0.90

0.99

0.74

Receivable days

Inventory Days

109

Payable days

100

Cash Conversion Cycle

106

Total Debt/Equity

38.16

5.52

2.47

1.41

1.54

1.19

0.90

0.66

Interest Cover

-2

-4

-1

-5

-2

Norris Medicines Ltd.

Pharmaceuticals & Drugs

BSE: 524414 | NSE: Not Listed

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Standalone Figures in Rs. Crores

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Annual Reports:

News Update

Norris Medicines Ltd.

Pharmaceuticals & Drugs

BSE: 524414 | NSE: Not Listed

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Standalone Figures in Rs. Crores

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Annual Reports:

News Update